Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 6

1.

Malignancy after renal transplantation in the new era of immunosuppression.

Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M.

Ann Transplant. 2011 Apr-Jun;16(2):14-8.

PMID:
21716180
2.

Post-transplant de novo malignancies in renal transplant recipients: the past and present.

Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW.

Transpl Int. 2006 Aug;19(8):607-20. Review.

PMID:
16827677
3.

Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression.

Melosky B, Karim M, Chui A, McBride M, Cameron EC, Yeung CK, Landsberg D, Shackleton C, Keown PA.

J Am Soc Nephrol. 1992 Jun;2(12 Suppl):S290-4. Review.

4.

Belatacept for kidney transplant recipients.

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.

Cochrane Database Syst Rev. 2014 Nov 24;11:CD010699. doi: 10.1002/14651858.CD010699.pub2. Review.

PMID:
25416857
5.

Urological malignancy after renal transplantation.

Besarani D, Cranston D.

BJU Int. 2007 Sep;100(3):502-5. Review.

6.

Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.

Marcén R.

Drugs. 2009 Nov 12;69(16):2227-43. doi: 10.2165/11319260-000000000-00000. Review.

PMID:
19852526
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk